CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to consumers.
The drugstore chain says it will charge $109.99 for a two-pack of the authorized generic version of Adrenaclick, a lesser-known treatment compared to EpiPen, which can cost more than $600.
CVS Health Corp., the nation's second-largest drugstore chain, says it cut the price of the generic version of Adrenaclick nearly in half. The lower price is now available at all CVS stores. The chain runs about 9,600 retail pharmacies in the United States, including several locations inside Target stores.
The emergency treatments are stocked by schools and parents of children with severe allergies. They are used to stop anaphylaxis, the potentially fatal allergic reactions to insect bites and stings and foods like nuts and eggs.
The syringes are filled with the hormone epinephrine, and they expire after a year. That often forces patients to fill new prescriptions even if they never used the old one.
Mylan NV began taking heat late last summer for its EpiPen pricing, which climbed more than 500 percent since 2007. A Congressional panel grilled CEO Heather Bresch in September about the soaring cost, which she has blamed in part on insurers, pharmacy benefits managers and other middlemen that stand between the drugmaker and the customer.
Mylan has since expanded the financial aid it offers customers and launched its own authorized generic in December, priced at $300 per two-pack.
But patients with no health insurance or plans that make them pay a high deductible before covering care can be exposed to the full price of the drug if they aren't aware of that financial aid or if they don't seek it.
CVS says the new price it is charging for the Adrenaclick generic applies to both insured patients and those who pay cash without coverage. It's what customers will pay at the pharmacy counter.
Additionally, Cigna has released a list of prescription drug changes and will no longer cover EpiPen effective Jan. 7, 2017.
According to CNNMoney, Cigna spokeswoman Karen Eldred said "The generic version, available now in pharmacies, has the same drug formulation and device functionality as the branded medication, but at a substantial cost savings."